MANNKIND CORP Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31)
MANNKIND CORP (MNKD) had Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) of $119.60 million as of 2013-09-30, per its 10-Q filed 2013-11-12.
Discontinued › Notes
us-gaap:LineOfCreditFacilityAmountOutstanding · last filed 2013-11-12
- 2013-09-30: Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) $119.60M.
- 2013-06-30: Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) $119.60M.
- 2013-03-31: Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) $119.60M.
- 2012-12-31: Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) $119.60M.
| Period end | Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) |
|---|---|
| 2013-09-30 | $119.60M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $119.60M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $119.60M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $119.60M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |